Advances in lymphoma maintenance therapy with rituximab
10.3969/j.issn.1000-8179.20141313
- VernacularTitle:利妥昔单抗在淋巴瘤维持治疗中的新进展
- Author:
Xiwen BI
;
Tingchao CHEN
;
Wenqi JIANG
- Publication Type:Journal Article
- Keywords:
rituximab;
malignant lymphoma;
maintenance therapy
- From:
Chinese Journal of Clinical Oncology
2014;(24):1612-1615
- CountryChina
- Language:Chinese
-
Abstract:
Rituximab is the first monoclonal antibody that has been approved for the treatment of lymphoma. Rituximab has shown significant efficacy in the treatment of B-cell non-Hodgkin's lymphomas, such as diffuse large B-cell and follicular lymphomas. Maintenance therapy with rituximab has further improved the prognosis in patients with follicular lymphoma. These patients responded to induction treatment. This antibody treatment has been recommended in treatment guidelines. The treatment strategy for lymphoma has continuously improved. Recent studies focused on how to improve the definition of the indication for maintenance therapy and how to optimize the current maintenance regimens. In this review, we summarized the main studies and the most recent advances on ritux-imab maintenance therapy in patients with lymphoma.
